NCT05033847

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,800 (actual)
• Sponsor: National Vaccine and Serum Institute, China · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.

Conditions

• COVID-19 Pneumonia
• Coronavirus Infections

Interventions

Type	Name	Description
BIOLOGICAL	Recombinant COVID-19 Vaccine (CHO cell)	Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
BIOLOGICAL	COVID-19 vaccine (Vero cells)	Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Timeline

• Start date: 2021-09-12
• Primary completion: 2023-11-01
• Completion: 2024-01-01
• First posted: 2021-09-05
• Last updated: 2023-02-02

Locations

1 site across 1 country: United Arab Emirates